TaiLai Biosciences
Disruptive biopsy products and services leveraging multiomics technology for advanced cancer screening and early intervention.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | - | |
| Total Funding | 000k | ||
TaiLai Biosciences is a biotechnology company specializing in advanced cancer screening and early intervention. Founded by medical experts and seasoned scientists, the company leverages proprietary multiomics technology and machine learning to provide disruptive biopsy products and services. TaiLai Biosciences collaborates with world-renowned hospitals and thought leaders to develop techniques that interpret molecular information for effective, non-invasive diagnosis. The company's core market includes healthcare providers and research institutions focused on cancer prevention and treatment. TaiLai Biosciences operates on a B2B (business-to-business) model, generating revenue through the sale of its biopsy products and diagnostic services. By enabling early detection and intervention, the company aims to significantly increase recovery rates for cancer patients.
Keywords: biotechnology, cancer screening, multiomics, machine learning, biopsy, non-invasive, early intervention, molecular information, healthcare, diagnostics.